Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
Eur J Clin Microbiol Infect Dis
; 40(10): 2235-2241, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-33782783
ABSTRACT
We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoensaio
/
Teste Sorológico para COVID-19
/
SARS-CoV-2
/
COVID-19
/
Anticorpos Antivirais
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article